{"content":[{"text":"rash, and mild bleeding. In severe cases, plasma leaks out of the circulatory system and can be \n fatal. There is currently no specific treatment for dengue and prevention depends solely on \n effective vector control measures. The global incidence of dengue has grown dramatically in recent \n decades. About half of the world's population is at risk for dengue and a recent study estimates that \n approximately 390 million people are infected each year. The World Health Organization estimates \n that 500,000 people with severe dengue require hospitalization each year, a large proportion of \n whom are children, and more than 20,000 of those affected die each year.","bbox":{"left":0.105882,"top":0.082256,"width":0.785062,"height":0.12132399999999999}},{"text":"About Visterra \n Visterra is a clinical-stage biopharmaceutical company focused on applying its novel Hierotope® \n platform to identify unique disease targets and to design and engineer precision antibody-based \n biological medicines against such targets that are not adequately addressed with conventional \n approaches. Visterra’s technology is uniquely capable of engineering biological medicines for \n infectious diseases that provide broad coverage across viral strains, including mutated strains, and in the \n case of endogenous targets, selectively modify the activity of targets that have limited surface area, are \n hard to access, have dynamic structures, and/or are similar to other proteins in the body that should be \n avoided. Visterra’s lead product candidate, VIS410, is a monoclonal antibody in development as a \n single-dose administration for the treatment of hospitalized patients with influenza A, regardless of the \n viral strain. The company’s other product candidates are VIS649, a monoclonal antibody in \n development for the treatment of IgA nephropathy, VIS513, a monoclonal antibody in development as a \n single-dose administration for the treatment of dengue, and VIS705, an antibody-drug conjugate being \n developed as a single-dose curative therapy, engineered to kill all strains of the deadly Pseudomonas \n aeruginosa bacteria. In addition, Visterra has applied its Hierotope platform to develop novel \n modifications to the Fc region of an antibody, to enhance half-life by as much as ten-fold while \n maintaining and often improving effector function. These capabilities, called ViStar™ antibody Fc \n engineering, support the development of long-acting monoclonal antibodies for the extended protection \n in infectious diseases and less frequent administration in chronic diseases. For more information, visit \n www.visterrainc.com.","bbox":{"left":0.105882,"top":0.22165,"width":0.783652,"height":0.33415799999999996}},{"text":"###","bbox":{"left":0.485294,"top":0.608619,"width":0.029411999999999994,"height":0.01677899999999999}},{"text":"Media Contact: \n Kathryn Morris \n The Yates Network \n kathryn@theyatesnetwork.com \n Tel: 914-204-6412","bbox":{"left":0.11451,"top":0.643975,"width":0.234643,"height":0.08243900000000004}}],"images_bbox":[],"images_bbox_not_text_overlap":[]}